Monoamine Oxidase

Oxidase

MAO

Monoamine Oxidase

Monoamine Oxidase Isoform Specific Products:

Monoamine Oxidase Related Products (400)
Antibodies (2)
Monoamine Oxidase Isoform Comparison

By Effects:	Inhibitors (380) Ligand (1) Activators (2) Chemicals (2)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-151388

hMAO-B/MB-COMT-IN-1	Inhibitor	98.04%
hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC₅₀s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD).

HY-B1413

Eprobemide	Inhibitor	99.94%
Eprobemide is a non-competitive reversible inhibitor of monoamine oxidase A.

HY-N7598

Chrysophanol-1-O-β-gentiobioside	Inhibitor	≥99.0%
Chrysophanol-1-O-β-gentiobioside, an anthraquinone glycoside isolated from Cassia obtusifolia seeds. Chrysophanol-1-O-β-gentiobioside shows selective inhibition of hMAO-A isozyme activity (IC₅₀=96.15 μM).

HY-156255

MAO-B-IN-25	Inhibitor	99.11%
MAO-B-IN-25 (compound 92) is a selective MAO-B inhibitor with IC₅₀s of 0.5 nM and 240 nM for MAO-A and MAO-B, respectively.

HY-B1558A

Bifemelane hydrochloride	Inhibitor	99.86%
Bifemelane hydrochloride (MCI-2016) is a potent, selective and competitive inhibitor of monoamine oxidase A (MAO-A), with a K_i of 4.20 μM. Bifemelane hydrochloride also inhibits MAO-B noncompetitively with a K_i of 46.0 μM. Bifemelane hydrochloride has a potent antidepressant activity and can be used for the research of cognitive and emotional disturbances related to cerebrovascular disease.

HY-10400

Ladostigil hemitartrate	Inhibitor	98.90%
Ladostigil (TV-3326) hemitartrate is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hemitartrate exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil hemitartrate can be used for the research of depression and Alzheimer's disease. Ladostigil (hemitartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-149234

MAO-B-IN-18	Inhibitor	99.84%
MAO-B-IN-18 is a potent and selective MAO B inhibitor with IC₅₀s of 52 nM and 14 μM for hMAO B and hMAO A, respectively. MAO-B-IN-18 enables promising cytoprotective effects against hydrogen peroxide insults in neuroblastoma and astrocytes cultures.

HY-14260

RS 8359	Inhibitor
RS 8359 is a selective and reversible MAO-A inhibitor, with antidepressant activity.

HY-B1111

Amitraz	Inhibitor	99.65%
Amitraz is a non-systemic acaricide and insecticide with alpha-adrenergic agonist activity that interacts with octopamine receptors in the central nervous system and inhibits monoamine oxidase and prostaglandin synthesis.

HY-114286

PXS-5153A	Inhibitor
PXS-5153A is a potent, selective, orally active and fast-acting lysyl oxidase like 2/3 enzymatic (LOXL2/LOXL3) inhibitor, with an IC₅₀ of <40 nM for LOXL2 across all mammalian species and an IC₅₀ of 63 nM for human LOXL3. PXS-5153A could reduce crosslinks and ameliorates fibrosis.

HY-10399A

Ladostigil hydrochloride	Inhibitor	99.94%
Ladostigil (TV-3326) hydrochloride is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO), with IC₅₀s of 37.1 and 31.8 μM for MAO-B and AChE, respectively. Ladostigil hydrochloride exhibits neuroprotective, antioxidant and anti-inflammatory activities. Ladostigil can be used for the research of depression and Alzheimer's disease. Ladostigil (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14200

(S)-Rasagiline	Inhibitor	99.80%
(S)-Rasagiline (TVP1022) is the relatively inactive S-enantiomer form of Rasagiline. Rasagiline is a highly potent selective irreversible MAO inhibitor with IC₅₀s of 4.43 nM and 412 nM for rat brain MAO B and A activity, respectively. (S)-Rasagiline is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-100975

TB5	Inhibitor	99.96%
TB5 is a potent, selective and reversible inhibitor of hMAO-B with a K_i value of 0.11±0.01 μM.

HY-151466

HIF-1α-IN-5	Inhibitor	99.95%
HIF-1α-IN-5 is a HIF-1α inhibitor with an IC₅₀ value of 24 nM (in HEK293T cell). HIF-1α-IN-5 also inhibits MAO-A activity. HIF-1α-IN-5 downregulates VEGF and PDK1 mRNA expressions under hypoxia. HIF-1α-IN-5 can be used in the research of cancer.

HY-122812

Maesopsin	Inhibitor	99.66%
Maesopsin is a phenolic compound, that can be isolated from Hoveniae Lignum.

HY-B1440

Ethaverine hydrochloride	Inhibitor	99.72%
Ethaverine hydrochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine hydrochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine hydrochloride can be used for research of peripheral vascular disease.

HY-N0453R

Hypericin (Standard)	Inhibitor
Hypericin (Standard) is the analytical standard of Hypericin. This product is intended for research and analytical applications. Hypericin is a naturally occurring substance found in Hyperlcurn perforatum L. Hypericin is an inhibitor of PKC (protein kinase C), MAO (monoaminoxidase), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450). Hypericin shows antitumor, antiviral, antidepressive activities, and can induce apoptosis.

HY-151498A

PXS-4787 hydrochloride	Inhibitor	99.71%
PXS-4787 hydrochloride is a specific and effective pan-LOX (lysyl oxidase) inhibitor for abolishing lysyl oxidase activity. PXS-4787 hydrochloride inhibits LOX with IC₅₀s of 2 μM (Bovine LOX), 3.2 μM (rh LOXL1), 0.6 μM (rh LOXL2), 1.4 μM (rh LOXL3), 0.2 μM (rh LOXL4), respectively. PXS-4787 hydrochloride reduces deposition and crosslinking of collagen I secreted by human fibroblasts.

HY-144635

Nrf2-ARE/hMAO-B/QR2 modulator 1	Inhibitor	98.44%
Nrf2-ARE/hMAO-B/QR2 modulator 1 is a Resveratrol-based multitarget-directed ligands with IC₅₀s of 8.05, 9.83 and 0.57 μM for hMAO-B, NRF2 and QR2. Nrf2-ARE/hMAO-B/QR2 modulator 1 has neuroprotection, decreasing ROS production in okadaic acid-treated mice hippocampal slices.

HY-13339

Brofaromine	Inhibitor	99.60%
Brofaromine (CGP 11305A) is a monoamine oxidase (MAO) inhibitor with IC₅₀ of 0.2 μM for MAO-A.

Tranylcypromine hydrochloride	MAO-A, IC₅₀: 2.3 μM	MAO-B, IC₅₀: 0.95 μM	99.90%
Selegiline hydrochloride		MAO-B, IC₅₀: 51 nM	99.94%
Pargyline	MAO-A, Ki: 13 μM	MAO-B, Ki: 0.5 μM	99.92%
Pargyline hydrochloride	MAO-A, Ki: 13 μM	MAO-B, Ki: 0.5 μM	99.91%
Norharmane	MAO-A, IC₅₀: 6.5 μM	MAO-B, IC₅₀: 4.7 μM	99.46%
Rasagiline	rMAO-A, IC₅₀: 412 nM	rMAO-B, IC₅₀: 4.43 nM	99.88%
Safinamide	MAO-A, IC₅₀: 580 μM	MAO-B, IC₅₀: 98 nM	99.89%
Moclobemide	MAO-A, IC₅₀: 6.061		99.12%
Rasagiline mesylate	rMAO-A, IC₅₀: 412 nM	rMAO-B, IC₅₀: 4.43 nM	99.82%
Tedizolid phosphate	MAO-A	MAO-B	99.65%
Harmane	hMAO-A, IC₅₀: 0.5 μM	MAO-B, IC₅₀: 5 μM	99.91%
1,4-Naphthoquinone	MAO-A, Ki: 7.7 μM	MAO-B, Ki: 1.4 μM	99.97%
Xanthone	MAO-A, IC₅₀: 0.84 μM		99.97%
Safinamide mesylate	MAO-A, IC₅₀: 580 nM	MAO-B, IC₅₀: 98 nM	99.87%
Desmethoxyyangonin	MAO-A, IC₅₀: 1.850 μM	MAO-B, IC₅₀: 0.123 μM	99.47%
Osthenol	hMAO-A, Ki: 0.26 μM hMAO-A, IC₅₀: 0.74 μM		99.27%
(E)-8-(3-Chlorostyryl)caffeine		MAO-B, Ki: 70 nM	99.4%
Tisolagiline		MAO-B, IC₅₀: 8 nM	99.97%
Methyl citrate		MAO-B, IC₅₀: 0.23 mM	≥98.0%
LSD1/HDAC6-IN-2	MAO-A, IC₅₀: 5 nM	MAO-B, IC₅₀: 6600 nM	99.66%
MAO-A inhibitor 1	MAO-A, IC₅₀: 100 μM		98.55%
MAO-IN-M30 dihydrochloride	MAO-A, IC₅₀: 37 nM	MAO-B, IC₅₀: 57 nM	99.25%
TC-2153	MAO-A		98.73%
Chrysophanol-1-O-β-gentiobioside	MAO-A, IC₅₀: 96.15 μM		≥99.0%
MAO-B-IN-25	MAO-A, IC₅₀: 240 nM	MAO-B, IC₅₀: 0.5 nM	99.11%
Bifemelane hydrochloride	MAO-A, Ki: 4.2 μM	MAO-B, Ki: 46 μM	99.86%
Ladostigil hemitartrate		MAO-B, IC₅₀: 37.1 nM	98.90%
MAO-B-IN-18	hMAO-A, IC₅₀: 14 μM	hMAO-B, IC₅₀: 52 nM	99.84%
Ladostigil hydrochloride		MAO-B, IC₅₀: 37.1 μM	99.94%
MAO-A/5-HT2AR-IN-1	MAO-A, IC₅₀: 0.004 ± 0. μM	MAO-B, IC₅₀: 1.05 ± 0.0 μM	99.71%
Ladostigil		MAO-B, IC₅₀: 37.1 μM
MAO-B-IN-8		MAO-B	98.03%
Tetrahydroharmine		MAO-B, IC₅₀: 74 nM	98.00%
ASS234	MAO-A, IC₅₀: 5.2 nM	MAO-B, IC₅₀: 43 nM	99.6%
(Rac)-Rasagiline		MAO-B
Tetrindole mesylate	MAO-A		99.93%
MC4762		MAO-B, IC₅₀: 0.182 μM
Selegiline		MAO-B, IC₅₀: 51 nM
MAO A/HDAC-IN-1	MAO-A
hMAO-B-IN-7		hMAO-B, IC₅₀: 0.79 μM
MAO-B-IN-39	MAO-A, IC₅₀: >30 μM	MAO-B, IC₅₀: 3.61 μM
MAO-B-IN-21		MAO-B
MAO-B-IN-37	MAO-A, IC₅₀: 16 μM	MAO-B, IC₅₀: 0.27 μM
Befloxatone	MAO-A, IC₅₀: 4 nM	MAO-B, IC₅₀: 300 nM
Dual AChE-MAO B-IN-2		MAO-B, Ki: 4.5 μM
AChE-IN-60	MAO-A, IC₅₀: 353 nM	MAO-B, IC₅₀: 716 nM
MAO-A inhibitor 2	MAO-A, IC₅₀: 14.3 μM	MAO-B, IC₅₀: 106 μM
MAO-B-IN-9		MAO-B, IC₅₀: 0.178 ± 0. μM	99.70%
ChEs/MAOs-IN-2	MAO-A, IC₅₀: 0.10 μM	MAO-B, IC₅₀: 0.20 μM
Esuprone	MAO-A, IC₅₀: 7.3 nM
LSD1-IN-17	MAO-A, IC₅₀: 0.028 ± 0. μM	MAO-B, IC₅₀: 0.820 ± 0. μM
(±)-Amiflamine	MAO-A, pIC₅₀: 5.57		99.23%
MAO-B-IN-13		MAO-B, IC₅₀: 10 nM
Cimoxatone	MAO-A
hMAO-B-IN-11		hMAO-B, IC₅₀: 0.11 μM
LSD1-IN-34	MAO-A, IC₅₀: 18.46 nM	MAO-B, IC₅₀: 8481.67 nM
PSB-1491		hMAO-B, IC₅₀: 0.0386 nM
Neuroinflammatory-IN-2		MAO-B, IC₅₀: 10.30 μM
AChE/BChE/MAO-B-IN-3		hMAO-B, IC₅₀: 0.0359 μM
MAO-B-IN-33	MAO-A, IC₅₀: 26.805 μM	MAO-B, IC₅₀: 0.021 μM
MAO-IN-6		MAO-B, IC₅₀: 0.09 μM
AChE/MAO-IN-1	hMAO-A, IC₅₀: 0.1108 μM hMAO-A, Ki: 0.1069 μM	hMAO-B, IC₅₀: 0.0409 μM
hMAO-B-IN-2		MAO-B, IC₅₀: 4 nM
MAO-B-IN-16	hMAO-A, IC₅₀: ＞100 μM	hMAO-B, IC₅₀: 1.55 μM
1-Methyl-2-undecyl-4(1H)-quinolone		MAO-B, IC₅₀: 15.3 μM MAO-B, Ki: 9.91 μM
LSD1-IN-15	MAO-A, IC₅₀: 0.028 ± 0. μM	MAO-B, IC₅₀: 0.327 ± 0. μM
CHBO4		hMAO-B, IC₅₀: 0.031 μM
MAO-B-IN-7		MAO-B, IC₅₀: 0.3 μM
MAO-B-IN-14		hMAO-B, IC₅₀: 0.95 μM hMAO-B, Ki: 0.55 μM
AChE/BChE/MAO-B-IN-2		MAO-B, IC₅₀: 48.2 nM
MAO-B ligand-1	hMAO-A, IC₅₀: 22.57 nM	hMAO-B, IC₅₀: 3.83 nM
AChE/MAO-B-IN-3		hMAO-B, IC₅₀: 0.0456 μM
MAO-B-IN-11		MAO-B, IC₅₀: 1.3 μM
MAO-B-IN-10	MAO-A, IC₅₀: 15.9 ± 0.1 μM	MAO-B, IC₅₀: 5.3 ± 0.22 μM
Multitarget AD inhibitor-2		MAO-B, IC₅₀: 0.45 μM
Desoxypeganine	MAO-A, IC₅₀: 2 μM
HDAC1/MAO-B-IN-1		MAO-B, IC₅₀: 99.0 nM
MAO-B-IN-3		MAO-B, IC₅₀: 96 nM
MAO-B-IN-5	MAO-A, IC₅₀: 0.204 μM	MAO-B, IC₅₀: 34.190 μM
LSD1-IN-26	MAO-A, IC₅₀: 1234.57 nM	MAO-B, IC₅₀: 3819.27 nM
Dual AChE-MAO B-IN-3		MAO-B, IC₅₀: 0.41 ± 0.0 μM
2-PAT	MAO-A, IC₅₀: 0.721 μM	MAO-B, IC₅₀: 14.6 μM
Harmane (Standard)	hMAO-A	MAO-B
MAO-B-IN-40	hMAO-A, IC₅₀: >100 μM	hMAO-B, IC₅₀: 0.493 μM
NDs-IN-1	hMAO-A	hMAO-B
AChE/BChE/MAO-B-IN-5		MAO-B, IC₅₀: 0.11 μM
MAO-B-IN-20	MAO-A, IC₅₀: >10 μM	MAO-B, IC₅₀: 0.037 μM
MAO-B-IN-38	MAO-A, IC₅₀: 21.46 μM	MAO-B, IC₅₀: 0.03 μM
AChE/BChE-IN-6		hMAO-B, IC₅₀: ＞ 100 μM
1-Methyl-2-nonyl-4(1H)-quinolone	MAO-A	MAO-B
MAO-B-IN-17	hMAO-A, IC₅₀: >100 μM	hMAO-B, IC₅₀: 5.08 μM	≥99.0%
MAO-B-IN-32		MAO-B, IC₅₀: 16 nM
AChE/BuChE/MAO-B-IN-1		hMAO-B, IC₅₀: 1.11 μM
Tisolagiline methylsulfate		MAO-B, IC₅₀: 8 nM
Moclobemide N-Oxide	MAO-A
FTEAA	MAO-A, IC₅₀: 0.52 μM	MAO-B, IC₅₀: 1.02 μM
MAO A/HSP90-IN-2	MAO-A, IC₅₀: 4.58 μM
MAO-B-IN-6	MAO-A, IC₅₀: 46.365 μM	MAO-B, IC₅₀: 0.019 μM
MAO-B-IN-30	MAO-A, IC₅₀: 19.176 μM	MAO-B, IC₅₀: 0.082 μM	98.53%
Monoamine Oxidase B inhibitor 5	hMAO-A, IC₅₀: 26014 nM	hMAO-B, IC₅₀: 67.3 nM
Monoamine Oxidase B inhibitor 6		MAO-B, IC₅₀: 0.11 μM MAO-B, Ki: 0.072 μM
LSD1-IN-12	MAO-A, Ki: 2.3 μM	MAO-B, Ki: 3.5 μM
AChE/BChE/MAO-B-IN-1		MAO-B, IC₅₀: 26.1 μM	99.57%
MAO-A/B-IN-3	MAO-A, IC₅₀: 67 nM	MAO-B, IC₅₀: 29 nM
MAO-B-IN-19		MAO-B, IC₅₀: 0.67 μM
MAO-B-IN-29		MAO-B
MAO-B-IN-15	hMAO-A, IC₅₀: >100 μM	hMAO-B, IC₅₀: 13.5 μM
Desoxypeganine hydrochloride	MAO-A, IC₅₀: 2 μM
AChE/MAO-B-IN-4		hMAO-B
Monoamine Oxidase B inhibitor 2	MAO-A, IC₅₀: 1150 nM	MAO-B, IC₅₀: 1.33 nM
(E)-CHBO4		MAO-B, IC₅₀: 0.023 μM
H3R antagonist 2		MAO-B, IC₅₀: 775 nM
AChE/BuChE/MAO-B-IN-2		hMAO-B, IC₅₀: 1.9 μM
MAO-B-IN-43	hMAO-A, Ki: 0.044 μM	hMAO-B, Ki: 0.004 μM
Monoamine Oxidase B inhibitor 1	MAO-A, IC₅₀: 810 nM	MAO-B, IC₅₀: 0.02 nM
MAO-A/SERT-IN-1	MAO-A
SL-25.1188		hMAO-B, Ki: 2.9 nM rMAO-B, Ki: 8.5 nM
Lazabemide hydrochloride		MAO-B, IC₅₀: 0.4 nM
AChE/MAO-IN-2	MAO-A, IC₅₀: 0.1116 μM	MAO-B, IC₅₀: 0.0412 μM
hAChE-IN-3		MAO-B, IC₅₀: 5.15 μM
MAO-B-IN-12		MAO-B, IC₅₀: 1.3 μM
COMT-IN-1	MAO-A, IC₅₀: 95.58 μM	MAO-B, IC₅₀: 58.82 μM
Methyl piperate		MAO-B
Monoamine oxidase/Aromatase-IN-1		MAO-B, IC₅₀: 39 nM
Eckol	hMAO-A, IC₅₀: 7.20 μM	hMAO-B, IC₅₀: 83.44 μM
Dual AChE-MAO B-IN-4		MAO-B, IC₅₀: 15 nM
LSD1-IN-16	MAO-A, IC₅₀: 0.024 ± μM	MAO-B, IC₅₀: 0.366 ± μM
PSB-1434		MAO-B, IC₅₀: 1.59 nM	98.05%
BChE/MAO-B-IN-1		MAO-B, IC₅₀: 20 nM
AChE-IN-82	hMAO-A, IC₅₀: 14.52 μM	hMAO-B, IC₅₀: 0.024 μM
5-HT6R/MAO-B modulator 1		MAO-B
MAO-B-IN-42		MAO-B, IC₅₀: 0.184 μM
MAO A/HSP90-IN-1	MAO-A, IC₅₀: 1.77 μM
Norharmine	MAO-A
Fabomotizole	MAO-A		99.96%
Tedizolid phosphate sodium	MAO-A	MAO-B
Harmane hydrochloride	hMAO-A, IC₅₀: 0.5 μM	MAO-B, IC₅₀: 5 μM
PSB-1410		hMAO-B, IC₅₀: 0.23 nM rMAO-B, IC₅₀: 1.01 nM	99.22%
SZV-558		rMAO-B, IC₅₀: 50 nM hMAO-B, IC₅₀: 60 nM
Brofaromine hydrochloride	MAO-A
2-APB hydrochloride	MAO-A
Acacetin 7-O-(6-O-malonylglucoside)	MAO-A, IC₅₀: 2.34 μM	MAO-B, IC₅₀: 1.87 μM
(-)-2-Phenylpropylamine	MAO-A, Ki: 584 μM	MAO-B, Ki: 156 μM
6,7-Dimethylisatin	MAO-A, IC₅₀: 20.3 μM	MAO-B, IC₅₀: 6.74 μM

Name
Email *

	Sorry, but the email address you supplied was invalid.

Monoamine Oxidase

Monoamine Oxidase

Monoamine Oxidase Isoform Specific Products:

Monoamine Oxidase Isoform Specific Products:

Monoamine Oxidase Related Products (400)

Antibodies (2)

Monoamine Oxidase Isoform Comparison

Monoamine Oxidase Related Products (400):